US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aspire Biopharma Holdings Inc.

0.0999

+0.00111.11%

Post-market: 0.10150.0016+1.60%17:42 EST

Volume:27.24M

Turnover:2.86M

Market Cap:10.74M

PE:-0.24

High:0.1090

Open:0.1090

Low:0.0988

Close:0.0988

52wk High:15.80

52wk Low:0.0880

Shares:107.48M

Float Shares:35.35M

Volume Ratio:2.22

T/O Rate:77.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4147

EPS(LYR):-0.0030

ROE:--

ROA:-195.11%

PB:-0.94

PE(LYR):-33.57

Loading ...

Overview Company News Filings

Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin Product

Aspire Biopharma Holdings Adds Dr. Mark J. Jaroszeski to Scientific Team

Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Quarterly Report

Aspire Biopharma Hldgs Q3 EPS $(0.04) Down From $(0.01) YoY, Sales $1.941K

Aspire Biopharma Holdings Inc - on Nov 11, Entered Eloc Agreement With Arena Business Solutions - SEC Filing

THOMSON REUTERS

Aspire Biopharma Holdings - Under Eloc Agreement, Co Has Right but Not Obligation to Direct Arena to Purchase up to $100 Mln of Co’s Stock

THOMSON REUTERS

Aspire Biopharma Announces $100 Million Unregistered Share Sale Under Equity Line Agreement

Aspire Biopharma Holdings Inc. held special shareholder meeting

Aspire Biopharma Faces Nasdaq Delisting After Compliance Failures

Aspire Biopharma Holdings Announces Breakthrough in Sublingual Drug Delivery with New Patent Application

Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Aspire Biopharma Announces New Clinical Trials for Sublingual Aspirin and Rapid-Acting ED Medication, Eyes 2025–2026 FDA Submissions

Aspire Biopharma Holdings Inc. Raises $7.75 Million Through Private Placement in Two Tranches

Aspire Biopharma Holdings Inc. Announces Date for Special Stockholders Meeting

Aspire Biopharma files to sell 147.18M shares of common stock for holders

Aspire Biopharma announces initial production order of 2M servings of BUZZ BOMB

Aspire Biopharma Holdings Inc. Announces Date for Special Stockholders Meeting

Aspire Biopharma Announces Breakthrough Clinical Trial Results for Sublingual Aspirin, Aiming for Accelerated FDA Approval

Aspire Biopharma Holdings Inc - on Aug 19, Enters Agreement to Sell $9.69 Mln Notes - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ASBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","market":"US","secType":"STK","nameCN":"Aspire Biopharma Holdings Inc.","latestPrice":0.0999,"timestamp":1764709200000,"preClose":0.0988,"halted":0,"volume":27238421,"hourTrading":{"tag":"盘后","latestPrice":0.1015,"preClose":0.0999,"latestTime":"17:42 EST","volume":566984,"amount":58048.60435792,"timestamp":1764715360206},"delay":0,"floatShares":35345600,"shares":107477178,"eps":-0.414708,"marketStatus":"Post-Mkt","change":0.0011,"latestTime":"12-02 17:42:41 EST","open":0.109,"high":0.109,"low":0.0988,"amount":2864550.3352018,"amplitude":0.103239,"askPrice":0.107,"askSize":4500,"bidPrice":0.1,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.414708,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0988,"preHourTrading":{"tag":"盘前","latestPrice":0.1077,"preClose":0.0988,"latestTime":"09:29 EST","volume":5912568,"amount":634147.3073430001,"timestamp":1764685793213},"postHourTrading":{"tag":"盘后","latestPrice":0.1015,"preClose":0.0999,"latestTime":"17:42 EST","volume":566984,"amount":58048.60435792,"timestamp":1764715360206},"volumeRatio":2.222896},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","floatShares":35345600,"roa":"-195.11%","roe":"--","lyrEps":-0.002976,"volumeRatio":2.222896,"shares":107477178,"dividePrice":0,"high":0.109,"amplitude":0.103239,"preClose":0.0988,"low":0.0988,"week52Low":0.088,"pbRate":"-0.94","psRate":"5531.67","week52High":15.8,"institutionHeld":0,"latestPrice":0.0999,"committee":-0.384615,"eps":-0.414708,"divideRate":0,"volume":27238421,"delay":0,"ttmEps":-0.414708,"open":0.109,"prevYearClose":11.5,"prevWeekClose":0.1057,"prevMonthClose":0.1057,"prevQuarterClose":0.206,"fiveDayClose":0.1,"twentyDayClose":0.3617,"sixtyDayClose":0.5117},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASBP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASBP","date":"2025-12-01","current":-0.23824,"percent":0.925926,"low":-107.647863,"twenty":-32.753656,"median":-1.10471,"eighty":-0.838948,"high":-0.235902,"avg":-12.267175,"sd":19.66125,"marketCap":11360337},"quantilePoints":[{"date":"2025-03-07","current":-61.718107,"twenty":-79.515888,"median":-61.718107,"eighty":-58.474317,"marketCap":40003023},{"date":"2025-03-14","current":-41.62384,"twenty":-63.871064,"median":-57.344015,"eighty":-54.828644,"marketCap":26978783},{"date":"2025-03-21","current":-49.388839,"twenty":-61.718107,"median":-55.259235,"eighty":-45.464716,"marketCap":32011722},{"date":"2025-03-28","current":-47.36506,"twenty":-59.766092,"median":-48.376949,"eighty":-45.613987,"marketCap":30699995},{"date":"2025-04-04","current":-38.75323,"twenty":-56.183571,"median":-46.367595,"eighty":-43.647619,"marketCap":25118177},{"date":"2025-04-11","current":-38.035578,"twenty":-55.34679,"median":-45.929755,"eighty":-40.946376,"marketCap":24653026},{"date":"2025-04-17","current":-39.57853,"twenty":-55.287942,"median":-45.474044,"eighty":-39.546954,"marketCap":25653101},{"date":"2025-04-25","current":-36.428037,"twenty":-53.967461,"median":-44.487272,"eighty":-38.006872,"marketCap":23611087},{"date":"2025-05-02","current":-25.763721,"twenty":-50.875815,"median":-42.879731,"eighty":-36.06634,"marketCap":16698936},{"date":"2025-05-09","current":-24.070062,"twenty":-48.174572,"median":-41.62384,"eighty":-32.456117,"marketCap":15601179},{"date":"2025-05-16","current":-8.64997,"twenty":-47.360753,"median":-40.170558,"eighty":-27.896584,"marketCap":11330354},{"date":"2025-05-23","current":-0.643502,"twenty":-46.76371,"median":-38.75323,"eighty":-25.110657,"marketCap":10952545},{"date":"2025-05-30","current":-1.730761,"twenty":-46.192459,"median":-37.963813,"eighty":-23.557658,"marketCap":29457944},{"date":"2025-06-06","current":-0.976857,"twenty":-45.929755,"median":-36.514155,"eighty":-4.677726,"marketCap":16626329},{"date":"2025-06-13","current":-1.091781,"twenty":-45.929755,"median":-34.956848,"eighty":-1.13913,"marketCap":18582368},{"date":"2025-06-20","current":-0.913361,"twenty":-45.88526,"median":-32.509654,"eighty":-1.103849,"marketCap":15545618},{"date":"2025-06-27","current":-0.879171,"twenty":-45.613987,"median":-30.966702,"eighty":-1.056614,"marketCap":14963696},{"date":"2025-07-03","current":-0.838948,"twenty":-45.240807,"median":-27.672677,"eighty":-0.926003,"marketCap":14279083},{"date":"2025-07-11","current":-0.994957,"twenty":-44.49445,"median":-25.763721,"eighty":-0.89957,"marketCap":16934405},{"date":"2025-07-18","current":-1.022827,"twenty":-44.487272,"median":-24.235121,"eighty":-0.913361,"marketCap":17408745},{"date":"2025-07-25","current":-1.492005,"twenty":-43.705031,"median":-23.47441,"eighty":-0.913361,"marketCap":25394273},{"date":"2025-08-01","current":-1.094942,"twenty":-43.417971,"median":-12.855253,"eighty":-0.926003,"marketCap":18636159},{"date":"2025-08-08","current":-0.957894,"twenty":-42.341491,"median":-1.730761,"eighty":-0.926003,"marketCap":16303583},{"date":"2025-08-15","current":-1.119076,"twenty":-41.810429,"median":-1.408829,"eighty":-0.936633,"marketCap":19046927},{"date":"2025-08-22","current":-1.407348,"twenty":-41.62384,"median":-1.381965,"eighty":-0.948126,"marketCap":26605351},{"date":"2025-08-29","current":-1.458172,"twenty":-41.494663,"median":-1.401585,"eighty":-0.950712,"marketCap":27566154},{"date":"2025-09-05","current":-1.427258,"twenty":-40.909001,"median":-1.428961,"eighty":-0.956458,"marketCap":26981748},{"date":"2025-09-12","current":-1.182832,"twenty":-39.815341,"median":-1.395821,"eighty":-0.96387,"marketCap":22360975},{"date":"2025-09-19","current":-1.153491,"twenty":-39.515377,"median":-1.375367,"eighty":-0.974558,"marketCap":21806284},{"date":"2025-09-26","current":-0.990278,"twenty":-38.902502,"median":-1.341067,"eighty":-0.987594,"marketCap":18720816},{"date":"2025-10-03","current":-1.100309,"twenty":-38.179108,"median":-1.232741,"eighty":-0.956458,"marketCap":20800907},{"date":"2025-10-10","current":-0.881819,"twenty":-37.978166,"median":-1.192915,"eighty":-0.950195,"marketCap":16670441},{"date":"2025-10-17","current":-0.836759,"twenty":-37.504515,"median":-1.176427,"eighty":-0.934507,"marketCap":15818594},{"date":"2025-10-24","current":-0.880247,"twenty":-36.758157,"median":-1.164494,"eighty":-0.913361,"marketCap":16640725},{"date":"2025-10-31","current":-0.986087,"twenty":-36.462484,"median":-1.14993,"eighty":-0.912711,"marketCap":18641575},{"date":"2025-11-07","current":-0.694243,"twenty":-35.704643,"median":-1.134878,"eighty":-0.909799,"marketCap":13124382},{"date":"2025-11-14","current":-0.275601,"twenty":-35.070237,"median":-1.124309,"eighty":-0.898954,"marketCap":5210132},{"date":"2025-11-21","current":-0.235902,"twenty":-33.9751,"median":-1.119076,"eighty":-0.881505,"marketCap":4838687},{"date":"2025-11-28","current":-0.553115,"twenty":-32.997658,"median":-1.106147,"eighty":-0.854611,"marketCap":11360337},{"date":"2025-12-01","current":-0.553115,"twenty":-32.753656,"median":-1.10471,"eighty":-0.838948,"marketCap":11360337}],"updateTime":1764683023974},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588056295","title":"Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056295","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056295?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:00","pubTimestamp":1764684026,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has submitted a Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration  for its lead product candidate, a fast-acting, high-dose sublingual aspirin formulation intended for the treatment of suspected acute myocardial infarction . This submission marks an important step in seeking FDA guidance on the clinical development strategy and confirmation of the proposed 505 regulatory pathway. No grant or funding involving Aspire or multiple organizations is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 02, 2025, and is solely responsible for the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7LMyND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2586250219","title":"Aspire Biopharma Holdings Adds Dr. Mark J. Jaroszeski to Scientific Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250219","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250219?lang=en_us&edition=fundamental","pubTime":"2025-11-26 22:00","pubTimestamp":1764165631,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced the addition of Dr. Mark J. Jaroszeski to its scientific team. Dr. Jaroszeski joins as a new member and is a tenured professor in the Department of Medical Engineering at the University of South Florida.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL2Tg3sp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2583682056","title":"Aspire Biopharma Holdings Inc. Files Amendment to 10-Q Quarterly Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682056?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:03","pubTimestamp":1763157810,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has filed an amendment to its 10-Q quarterly report for the financial quarter ended September 30, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL6KQBSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2583502812","title":"Aspire Biopharma Hldgs Q3 EPS $(0.04) Down From $(0.01) YoY, Sales $1.941K","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502812","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583502812?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:31","pubTimestamp":1763130681,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Hldgs (NASDAQ:ASBP) reported quarterly losses of $(0.04) per share. This is a 300 percent decrease over losses of $(0.01) per share from the same period last year.  The company reported $1.941 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48864104/aspire-biopharma-hldgs-q3-eps-0-04-down-from-0-01-yoy-sales-1-941k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QID","SQQQ","ASBP","MNQmain","NQmain","QLD","NVIW.SI","PSQ","USJW.SI","TQQQ","USAW.SI",".IXIC","BK4007","TSYW.SI"],"gpt_icon":0},{"id":"2583850612","title":"Aspire Biopharma Holdings Inc - on Nov 11, Entered Eloc Agreement With Arena Business Solutions - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583850612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583850612?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:02","pubTimestamp":1763125342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ113:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2583506430","title":"Aspire Biopharma Holdings - Under Eloc Agreement, Co Has Right but Not Obligation to Direct Arena to Purchase up to $100 Mln of Co’s Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506430?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:02","pubTimestamp":1763125342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ113:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2583506193","title":"Aspire Biopharma Announces $100 Million Unregistered Share Sale Under Equity Line Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506193","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506193?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:01","pubTimestamp":1763125301,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has entered into an Equity Line of Credit  Agreement with Arena Business Solutions Global SPC II, Ltd., allowing the company to sell up to $100 million in common stock to Arena over a period of up to 36 months. The shares will be issued in reliance on exemptions from registration under Section 4 of the Securities Act and Regulation D, as Arena is considered an accredited investor. The sale of these unregistered shares is subject to certain terms, including the effectiveness of a registration statement for the resale of the shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gath","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL3GZlhh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2581623700","title":"Aspire Biopharma Holdings Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581623700","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581623700?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:51","pubTimestamp":1762379482,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. held a special meeting of stockholders on November 4, 2025. At the meeting, stockholders approved granting the board discretionary authority to amend the certificate of incorporation to implement a reverse stock split at a ratio ranging from one-for-five to one-for-forty, to be determined at the board's discretion and effected within one year. Stockholders also approved the issuance of more than 19.99% of the outstanding shares of common stock upon exercise of certain convertible promissory notes, as well as the floor price at which the notes may be converted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL20XJKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2576064128","title":"Aspire Biopharma Faces Nasdaq Delisting After Compliance Failures","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576064128?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:16","pubTimestamp":1760735780,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced that it received a notice from the Nasdaq Stock Market LLC regarding its failure to comply with two key listing requirements: the minimum Market Value of Listed Securities  of $50 million and the minimum bid price rule. The company did not regain compliance within the designated 180-day period, leading Nasdaq staff to notify Aspire that its securities are subject to delisting. Aspire has requested a hearing before the Nasdaq Hearings Panel, which temporarily stays the suspension of its common stock and warrants. The company will present its plan to regain compliance and seek an extension, but there is no assurance that continued listing will be granted or that compliance will be achieved in the allotted time.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL2WX1n6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2573672268","title":"Aspire Biopharma Holdings Announces Breakthrough in Sublingual Drug Delivery with New Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2573672268","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573672268?lang=en_us&edition=fundamental","pubTime":"2025-10-06 20:30","pubTimestamp":1759753832,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its innovative sublingual drug delivery platform. The proprietary technology, which has not yet been presented at scientific conferences, is designed to enhance the pharmacokinetic performance of active pharmaceutical ingredients  by enabling rapid absorption through sublingual blood vessels. Key features of the platform include faster onset of action, reduced drug-food and drug-drug interactions, lower risk of gastrointestinal irritation, and ease of administration, particularly in emergency situations. Aspire believes this advancement could significantly improve the efficacy and safety of a wide range of medications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL2CxrC9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2572686796","title":"Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2572686796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572686796?lang=en_us&edition=fundamental","pubTime":"2025-10-03 23:30","pubTimestamp":1759505417,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. to Present Pipeline Updates at Noble Capital Markets Emerging Growth Virtual Equity Conference. Aspire Biopharma Holdings Inc. will participate in the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference on October 8-9, 2025. The company will present updates on its disruptive sublingual drug delivery technology, including its lead programs targeting FDA submission for sublingual high-dose aspirin and a sublingual ED medication in the second half of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 03, 2025, and is solely responsible for the information contained","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL1ylrTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2572868547","title":"Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2572868547","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572868547?lang=en_us&edition=fundamental","pubTime":"2025-10-03 02:44","pubTimestamp":1759430656,"startTime":"0","endTime":"0","summary":"U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday.\n\n\n\nThe Dow traded up 0.20% to 46,532.02 while the NASDAQ rose 0.34% to 22,833.17. The S&amp;P 500 also rose, gaining, 0.07% to 6,715.87.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/10/48002933/crude-oil-down-2-aspire-biopharma-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USAW.SI","BK4007","BK4600","BK4164","BK4526","USJW.SI",".IXIC","NQmain","BK4170","QID","BK4023","BK4082","TSYW.SI","PSQ","UFG","BK4603","MNQmain","FPAY","BK4144","NVIW.SI","NVNI","SQQQ","ANGO","QLD","BK4020","ASBP","BK4595","TQQQ"],"gpt_icon":1},{"id":"2572539271","title":"Aspire Biopharma Announces New Clinical Trials for Sublingual Aspirin and Rapid-Acting ED Medication, Eyes 2025–2026 FDA Submissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2572539271","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572539271?lang=en_us&edition=fundamental","pubTime":"2025-10-01 20:30","pubTimestamp":1759321826,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Announces New Clinical Trials for Sublingual Aspirin and Rapid-Acting ED Medication, Eyes 2025-2026 FDA Submissions. Aspire Biopharma Holdings Inc.  has announced upcoming milestones for its pipeline of sublingual drug delivery products. The company plans to submit a 505 New Drug Application  to the U.S. Food and Drug Administration  for its high-dose sublingual aspirin in the second half of 2025, following a review of clinical trial results with the agency. Additionally, Aspire intends to finalize the formulation and manufacture of a sublingual semaglutide product and conduct an initial Phase 1 pharmacokinetic clinical cross-over study in the first half of 2026. For its needle-free, rapid-acting erectile dysfunction medication, Aspire plans to develop and validate the manufacturing process and produce a cGMP batch in early 2026, with a Phase 1 clinical test scheduled for the second or third quarter of 2026. Results of these clinical studies have not yet been presented","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL8XFRPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2570830829","title":"Aspire Biopharma Holdings Inc. Raises $7.75 Million Through Private Placement in Two Tranches","url":"https://stock-news.laohu8.com/highlight/detail?id=2570830829","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570830829?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:11","pubTimestamp":1758921075,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has completed private placements with certain investors under a Securities Purchase Agreement, selling notes with an aggregate principal amount of $9,687,500 for a total subscription price of $7,750,000. The first tranche of $4,709,677 was funded on August 19, 2025, and a second tranche of $1,000,000 was funded on September 22, 2025. The document does not specify the number of shares issued or the names of the investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 26,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL5JD0Ln:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aspire Biopharma Holdings Inc. Raises $7.75 Million Through Private Placement in Two Tranches","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2569712988","title":"Aspire Biopharma Holdings Inc. Announces Date for Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2569712988","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569712988?lang=en_us&edition=fundamental","pubTime":"2025-09-24 00:40","pubTimestamp":1758645648,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a Special Meeting of Stockholders to be held on November 4, 2025, in Provo, Utah. The meeting's agenda includes a proposal to grant discretionary authority to the company's board of directors to amend the company's certificate of incorporation, facilitating a reverse stock split of all outstanding shares of Common Stock by a ratio in the range of one-for-five.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 23, 2025, and is solely responsible for the informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL7m9Pfw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2568285736","title":"Aspire Biopharma files to sell 147.18M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2568285736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568285736?lang=en_us&edition=fundamental","pubTime":"2025-09-19 05:00","pubTimestamp":1758229215,"startTime":"0","endTime":"0","summary":"16:58 EDT Aspire Biopharma (ASBP) files to sell 147.18M shares of common stock for holders Published first on TheFly – the ultimate source for real...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-to-sell-147-18m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-to-sell-147-18m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2567100220","title":"Aspire Biopharma announces initial production order of 2M servings of BUZZ BOMB","url":"https://stock-news.laohu8.com/highlight/detail?id=2567100220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567100220?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:55","pubTimestamp":1758027323,"startTime":"0","endTime":"0","summary":"Aspire Biopharma (ASBP) Holdings announced a strategic initiative to rapidly increase the production capacity of its BUZZ BOMB single dose caffeine...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-announces-initial-production-order-of-2m-servings-of-buzz-bomb-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-announces-initial-production-order-of-2m-servings-of-buzz-bomb-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2566116637","title":"Aspire Biopharma Holdings Inc. Announces Date for Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2566116637","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566116637?lang=en_us&edition=fundamental","pubTime":"2025-09-09 05:11","pubTimestamp":1757365875,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a Special Meeting of Stockholders scheduled for November 4, 2025, in Provo, UT. During this meeting, stockholders will vote on granting discretionary authority to the company's board of directors to amend the company's certificate of incorporation. This amendment involves effecting a reverse stock split of all outstanding shares of common stock by a ratio in the range of one-for-five.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2025, and is solely re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL7mkw9x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2564888395","title":"Aspire Biopharma Announces Breakthrough Clinical Trial Results for Sublingual Aspirin, Aiming for Accelerated FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2564888395","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564888395?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:30","pubTimestamp":1756902656,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings, Inc.  has announced positive final results from its randomized, crossover bioavailability trial involving its investigational new sublingual aspirin product. The study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of the sublingual aspirin compared to chewed uncoated aspirin tablets. Results demonstrated that the sublingual aspirin produced higher and more rapid mean plasma concentrations of acetylsalicylic acid, indicating faster inhibition of serum thromboxane B2 , a biomarker for platelet aggregation. This rapid action is crucial during suspected heart attacks to prevent permanent heart muscle damage. Aspire plans to review these results with the U.S. Food and Drug Administration  for a potential regulatory submission for accelerated approval in the third quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL1lpYG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2561283936","title":"Aspire Biopharma Holdings Inc - on Aug 19, Enters Agreement to Sell $9.69 Mln Notes - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2561283936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561283936?lang=en_us&edition=fundamental","pubTime":"2025-08-23 05:20","pubTimestamp":1755897655,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nFWN3UE0RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ASBP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}